Pajjiż: Ingilterra
Lingwa: Ingliż
Sors: MHRA (Medicines & Healthcare Products Regulatory Agency)
Lacidipine
Dowelhurst Ltd
C08CA09
Lacidipine
2mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02060200
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU_._ • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1 What Motens is and what it is used for 2 What you need to know before you take Motens 3 How to take Motens 4 Possible side effects 5 How to store Motens 6 Contents of the pack and other information 1. WHAT MOTENS IS AND WHAT IT IS USED FOR Motens contains a medicine called lacidipine. This belongs to a group of medicines called ‘calcium channel blockers’. Motens helps to relax your blood vessels so that they get wider. This helps the blood to flow more easily and lowers the blood pressure. Motens tablets taken regularly as prescribed by your doctor will help to lower your blood pressure (to treat hypertension). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MOTENS DO NOT TAKE MOTENS IF: • You are pregnant, likely to get pregnant or are breast-feeding • You are allergic (hypersensitive) to lacidipine, other calcium channel blocker medicines or any of the other ingredients of this medicine (listed in section 6) • You have the heart problem ‘aortic stenosis’. This is a narrowing of a valve in your heart, which restricts blood flow • You have had a heart attack within the last month Do not take if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Motens. • You should stop taking Motens if you get chest pain (angina) or a fast, weak pulse, rapid shallow breathing, low blood pressure, cold clammy skin, blue lips or feel dizzy, faint, weak or sick TAKE SPECIAL CARE WITH MOTENS Check with your doctor or p Aqra d-dokument sħiħ
1 NAME OF THE MEDICINAL PRODUCT Motens 2 mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing lacidipine 2 mg. Excipient with known effect: Lactose 277.25 mg per tablet. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film coated tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS MOTENS is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including β -adrenoceptor antagonists, diuretics, and ACE-inhibitors. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _ADULTS: _ The treatment of hypertension should be adapted to the severity of the condition, and according to the individual response. The recommended initial dose is 2 mg once daily. The dose may be increased to 4 mg (and then, if necessary, to 6 mg) after adequate time has been allowed for the full pharmacological effect to occur. In practice, this should not be less than 3 to 4 weeks. Daily doses above 6 mg have not been shown to be significantly more effective. MOTENS should be taken at the same time each day, preferably in the morning. Treatment with MOTENS may be continued indefinitely. _PATIENTS WITH HEPATIC IMPAIRMENT: _ Lacidipine is metabolised primarily by the liver and therefore in patients with hepatic impairment, the bioavailability of MOTENS may be increased and the hypotensive effect enhanced. These patients should be carefully monitored, and in severe cases, a dose reduction may be necessary. _ _ _PATIENTS WITH KIDNEY DISEASE: _ As MOTENS is not cleared by the kidneys, the dose does not require modification in patients with kidney disease. _ _ _PAEDIATRIC POPULATION: _ No experience has been gained with MOTENS in children. Method of administration For oral administration. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. MOTENS should only be used with great care in patients with a previous allergic reaction to another dihydropyridine because there is a theoretical r Aqra d-dokument sħiħ